MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Business”), a professional stage pharmaceutical company devoted to expanding healthy lifespan, today announced that the initial patient has actually been enlisted in the Company’s Phase 2 clinical test of lead prospect MYMD-1, a dental immune regulator medicine, as a treatment for delaying aging and also expanding healthy lifespan.
The primary endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to achieve a decrease in the circulating levels of (TNF-α), growth death element receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that create inflammation and also aid trigger the procedure of aging. The secondary measures of the test will certainly be the security, tolerability, as well as pharmacokinetics in this populace of patients.
” In a Phase 1 medical trial of MYMD-1, we demonstrated the drug’s statistically significant effectiveness in decreasing degrees of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the key endpoint for our Stage 2 research, which we believe placements us well for a successful Phase 2 end result,” claimed Chris Chapman, M.D., Head Of State, Supervisor and Principal Medical Police Officer of MyMD. “The initiation of individual registration in this study breakthroughs our mission to slow the aging procedure, protect against loss of muscle tissue in aging, restriction frailty, and prolong healthy life expectancy.”
MyMD has mentioned that there are no FDA-approved drugs for dealing with aging conditions and expanding healthy life-span people, a market expected to be at least $600 billion by 20251 according to a significant financial investment bank. TNF-α blockers are the most proposed medicines by profits, a global market of around $40 billion each year,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would certainly enhance life span by one year deserves $38 trillion as well as by 10 years is worth $367 trillion.
Along with aging, MYMD-1’s unique action in controling the body immune system and treating persistent swelling is being established for the treatment of autoimmune disease, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory bowel illness.
” We intend to start composing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The rising prevalence of rheumatoid arthritis and various other autoimmune and inflammatory diseases are driving need for TNF inhibitors like MYMD-1, and also our team believe our by mouth provided medication with extremely reduced toxicity would certainly be disruptive to the $60 billion market for RA if accepted by the FDA for this indication.”
Rheumatoid joint inflammation affects around 40 million people worldwide.4.
Initially established for autoimmune diseases, MYMD-1’s key objective is to slow down the aging process, avoid sarcopenia and also frailty, as well as prolong healthy and balanced lifespan. Due to the fact that it can go across the blood-brain barrier and get to the central nervous system (CNS), MYMD-1 is additionally placed to be a feasible therapy for brain-related disorders. Its system of activity and effectiveness in illness consisting of several sclerosis (MS) and thyroiditis have been examined via partnerships with a number of scholastic organizations. MYMD-1 is also revealing guarantee in pre-clinical researches as a possible therapy for article- COVID-19 problems and also as an anti-fibrotic and anti-proliferation therapeutic.
MYMD-1 has revealed effectiveness in pre-clinical research studies in managing the body immune system by executing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a vehicle driver of persistent inflammation. Unlike various other treatments, MYMD-1 has been displayed in these pre-clinical research studies to selectively block TNF-α when it comes to be overactivated in autoimmune diseases and cytokine storms, yet not obstruct it from doing its normal task of being an initial responder to any kind of routine type of moderate infection. MYMD-1’s simplicity of oral application is one more differentiator compared to presently readily available TNF-α blockers, all of which call for distribution by shot or mixture. No authorized TNF prevention has actually ever been dosed orally. On top of that, the medicine is not immunosuppressive and also has actually not been revealed to create the major side effects typical with typical therapies that treat swelling.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical business devoted to expanding healthy lifespan, is concentrated on developing 2 novel healing platforms that treat the causes of disease rather than only dealing with the symptoms. MYMD-1 is a medicine platform based upon a scientific stage tiny molecule that regulates the immune system to regulate TNF-α, which drives persistent inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, boost longevity, and also treat autoimmune diseases and COVID-19- associated anxiety. The Company’s second medication platform, Supera-CBD, is being established to treat chronic pain, addiction and also epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and is being created to deal with and surpass the rapidly growing CBD market, which includes both FDA approved medicines and CBD items not presently regulated as medicines. For more information, see www.mymd.com.